These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38099955)

  • 1. A direct healthcare cost analysis of recombinant LH versus hMG supplementation on FSH during controlled ovarian hyperstimulation in the GnRH-antagonist protocol.
    Chang JC; Yi YC; Chen YF; Guu HF; Kung HF; Chen LY; Chuan ST; Chang YM; Chen MJ
    Arch Gynecol Obstet; 2024 Feb; 309(2):699-706. PubMed ID: 38099955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective, matched case-control study of recombinant LH versus hMG supplementation on FSH during controlled ovarian hyperstimulation in the GnRH-antagonist protocol.
    Chen MJ; Yi YC; Guu HF; Chen YF; Kung HF; Chang JC; Chuan ST; Chen LY
    Front Endocrinol (Lausanne); 2022; 13():931756. PubMed ID: 36046790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human LH supplementation versus supplementation with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocol: a matched case-control study.
    Bühler KF; Fischer R
    Gynecol Endocrinol; 2012 May; 28(5):345-50. PubMed ID: 22115012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders.
    Humaidan P; Chin W; Rogoff D; D'Hooghe T; Longobardi S; Hubbard J; Schertz J;
    Hum Reprod; 2017 Mar; 32(3):544-555. PubMed ID: 28137754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant LH supplementation improves cumulative live birth rates in the GnRH antagonist protocol: a multicenter retrospective study using a propensity score-matching analysis.
    Wang M; Huang R; Liang X; Mao Y; Shi W; Li Q
    Reprod Biol Endocrinol; 2022 Aug; 20(1):114. PubMed ID: 35941630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Supplementation with human menopausal gonadotropin in the gonadotropin-releasing hormone antagonist cycles of women with high AMH: Pregnancy outcomes and serial hormone levels.
    Chen LH; Chin TH; Huang SY; Yu HT; Chang CL; Huang HY; Wang HS; Soong YK; Wu HM
    Taiwan J Obstet Gynecol; 2021 Jul; 60(4):739-744. PubMed ID: 34247817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosing Characteristics of Recombinant Human Luteinizing Hormone or Human Menopausal Gonadotrophin-Derived LH Activity in Patients Undergoing Ovarian Stimulation: A German Fertility Database Study.
    Strezsak V; Allignol A; Bühler K; Fischer R; Hubbard J; Longobardi S; Lispi M; Schertz J; Verpillat P
    Gynecol Obstet Invest; 2023; 88(4):214-225. PubMed ID: 37369184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of recombinant human follicle-stimulating hormone alfa(r-hFSH) and urinary highly purified menopausal gonadotropin (hMG) based on data from a large German registry.
    Bühler K; Roeder C; Schwarze JE; Lispi M; Allignol A; Falla E; Lukyanov V; D Hooghe T; Fischer R
    Best Pract Res Clin Obstet Gynaecol; 2022 Dec; 85(Pt B):188-202. PubMed ID: 35304097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists.
    Frydman R; Howles CM; Truong F
    Hum Reprod; 2000 Mar; 15(3):520-5. PubMed ID: 10686190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of recombinant human FSH: recombinant human LH combination treatment versus recombinant human FSH alone for assisted reproductive technology in women aged 35-40 years.
    Bielfeld AP; Schwarze JE; Verpillat P; Lispi M; Fischer R; Hayward B; Chuderland D; D'Hooghe T; Krussel JS
    Reprod Biomed Online; 2024 Jun; 48(6):103725. PubMed ID: 38593745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of different gonadotropin combinations to support ovulation induction in WHO type I anovulation infertility: clinical evidences of human recombinant FSH/human recombinant LH in a 2:1 ratio and highly purified human menopausal gonadotropin stimulation protocols.
    Carone D; Caropreso C; Vitti A; Chiappetta R
    J Endocrinol Invest; 2012 Dec; 35(11):996-1002. PubMed ID: 23095369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of adding hp-hMG in r-FSH started GnRH antagonist cycles on ART outcome.
    Kan O; Simsir C; Atabekoglu CS; Sonmezer M
    Gynecol Endocrinol; 2019 Oct; 35(10):869-872. PubMed ID: 30973022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadotrophins for ovulation induction in women with polycystic ovary syndrome.
    Weiss NS; Kostova E; Nahuis M; Mol BWJ; van der Veen F; van Wely M
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD010290. PubMed ID: 30648738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of outcomes from in vitro fertilization cycles stimulated with either recombinant luteinizing hormone (LH) or human chorionic gonadotropin acting as an LH analogue delivered as human menopausal gonadotropins, in subjects with good or poor ovarian reserve: a retrospective analysis.
    Dahan MH; Agdi M; Shehata F; Son W; Tan SL
    Eur J Obstet Gynecol Reprod Biol; 2014 Jan; 172():70-3. PubMed ID: 24314801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG HP) in assisted reproductive technology (ART) treatments: a non-interventional study in Germany.
    Bühler KF; Fischer R; Verpillat P; Allignol A; Guedes S; Boutmy E; Bilger W; Richter E; D'Hooghe T
    Reprod Biol Endocrinol; 2021 Jun; 19(1):90. PubMed ID: 34134695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimising Follicular Development, Pituitary Suppression, Triggering and Luteal Phase Support During Assisted Reproductive Technology: A Delphi Consensus.
    Orvieto R; Venetis CA; Fatemi HM; D'Hooghe T; Fischer R; Koloda Y; Horton M; Grynberg M; Longobardi S; Esteves SC; Sunkara SK; Li Y; Alviggi C
    Front Endocrinol (Lausanne); 2021; 12():675670. PubMed ID: 34040586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probabilistic cost-effectiveness analysis of controlled ovarian stimulation with recombinant FSH plus recombinant LH vs. human menopausal gonadotropin for women undergoing IVF.
    Mennini FS; Marcellusi A; Viti R; Bini C; Carosso A; Revelli A; Benedetto C
    Reprod Biol Endocrinol; 2018 Jul; 16(1):68. PubMed ID: 30021630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study.
    Humaidan P; Bungum M; Bungum L; Yding Andersen C
    Reprod Biomed Online; 2004 Jun; 8(6):635-43. PubMed ID: 15169576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.